Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 16, 2021

SELL
$7.84 - $14.22 $228,379 - $414,228
-29,130 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$9.93 - $33.26 $289,260 - $968,863
29,130 New
29,130 $385,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $345M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Crawford Lake Capital Management, LLC Portfolio

Follow Crawford Lake Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Crawford Lake Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Crawford Lake Capital Management, LLC with notifications on news.